tailieunhanh - Báo cáo y học: "Phenotype and functional changes of Vγ9/Vδ2 T lymphocytes in Behçet's disease and the effect of infliximab on Vγ9/Vδ2 T cell expa"nsion, activation and cytotoxicity

Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học General Psychiatry cung cấp cho các bạn kiến thức về ngành y đề tài: Phenotype and functional changes of Vγ9/Vδ2 T lymphocytes in Behçet's disease and the effect of infliximab on Vγ9/Vδ2 T cell expansion, activation and cytotoxicity. | Accardo-Palumbo et al. Arthritis Research Therapy 2010 12 R109 http content 12 3 R109 RESEARCH ARTICLE Open Access Phenotype and functional changes of Vy9 VÔ2 T lymphocytes in Behcet s disease and the effect of infliximab on Vy9 VÔ2 T cell expansion activation and cytotoxicity Antonina Accardo-Palumbo Anna Rita Giardina Francesco Ciccia Angelo Ferrante Alfonso Principato Rosalia Impastato Ennio Giardina and Giovanni Triolo Abstract Introduction Infliximab is a chimeric monoclonal antibody against tumor necrosis factor alpha TNF-a that has been introduced recently for Behpet s disease BD patients who were resistant to standard treatment. The aim of this study was to analyse the functional changes of Vy9 Võ2 T lymphocytes in both active and inactive disease and the effect of infliximab on Vy9 Võ2 T cell expansion activation and cytotoxicity. Methods We investigated 1 cell expansion 2 expression of TNFRII receptor 3 perforin and gamma interferon IFN content 4 release of granzyme A GrA and 5 phenotype changes in vitro and in vivo in Vy9 Võ2 T lymphocytes by means of fluorescence-activated cell sorter analysis of lymphocyte cultures from patients with active and inactive BD and healthy subjects. Results Cell expansion expression of TNFRII perforin and gamma IFN content and release of granzyme A were significantly higher in active patients. In vitro and ex vivo treatment with infliximab resulted in a significant reduction of all parameters together with changes in the phenotype of Vy9 Võ2 T cells. Conclusions All together these data indicate that infliximab is capable of interfering with Vy9 Võ2 T cell function in BD and although cell culture models cannot reliably predict all potential effects of the drug in vivo our results present the possibility that this drug may find use in a range of immunological disorders characterized by dysregulated cell-mediated immunity. Introduction Behẹet s disease BD is a multisystemic inflammatory disorder .